Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

Latest News

JANUARY 19, 2022
3 min read

Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program

Geneva, Switzerland, and Paris, France, January 19, 2022Selexis SA, a JSR Life Sciences company, and Inotrem SA, an...

Read More
JANUARY 12, 2022
4 min read

Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx’s Acute Myeloid Leukemia (AML) CDX Bispecific Antibody to Human Trials

Hemogenyx Pharmaceuticals will leverage Selexis’ SUREtechnology Platform™ of protein expression technologies and...

Read More
NOVEMBER 1, 2021
3 min read

Meet Selexis During Key Industry Conferences to Learn About the Latest Innovations in Cell Line Development

Geneva, Switzerland, November 1, 2021Selexis SA, a JSR Life Sciences company, today announced that business and...

Read More